Wilson Disease Drugs Market: Global Industry Analysis and Forecast (2023-2029) Trends, Statistics, Dynamics, Segmentation by Drug Type, Distribution Channel, and Region

Wilson Disease Drugs Market size was valued at USD 637.36 Mn. in 2022 and the total Wilson Disease Drugs revenue is expected to grow by 4.4 % from 2023 to 2029, reaching nearly USD 861.6 Mn.
Wilson Disease Drugs Market Overview:
Wilson's disease is a genetic condition in which copper accumulates in the body, primarily in the liver and brain. Copper buildup can cause serious symptoms if left untreated. Medication is used to remove excess copper and prevent further copper buildup. If a patient only has one faulty gene, he or she will not become ill, but will be a carrier and can pass the gene on to their children. Wilson's disease symptoms typically appear between the ages of 12 and 23, according to National Library of Medicine data, and untreated patients can live for up to 40 years.

Wilson’s diseased patents have increased by up to 26% according to MMR research. In recent years, there has been an increase in demand for Wilson disease drugs from healthcare workers is boosting the demand for the Wilson disease drugs market. On the other hand, early detection and treatment of Wilson's disease may help people live longer lives. Because copper is not properly eliminated in Wilson's disease, it accumulates in the body above normal levels. Symptoms of Wilson's disease include swelling, fatigue, stomach pain, and uncontrolled or poorly coordinated motions between the ages of 12 and 23.

Increased drug demand for Penicillamine, Trientine, and Zinc from North America and Europe for the treatment of Wilson disease is boosting the Wilson disease drug market and is expected to same during the forecast period. Medications such as D-Penicillamine and Trientine are frequently used in treatment because they cause the organs, typically the liver, to release extra copper into the bile, which carries copper, waste products, and toxins to the digestive tract and excretes. Once in the bloodstream, it can be removed from the body via the kidneys. Wilson's disease is caused by disruptions or changes (mutations) in the ATP7B gene, which is involved in the transfer of excess copper from the liver to the bile, where it is eventually excreted from the body via the intestines. All these aspects are expected to boost the demand for the Wilson Disease Drugs Market.To know about the Research Methodology :- Request Free Sample Report
Wilson Disease Drugs Market Dynamics:
Wilson Disease Drugs Market Drivers

Increasing awareness among the people for disease treatment

More people are visiting clinics with complaints of abdominal pain, dark urine or light stool color, jaundice, mood changes, anxiety and depression, disruptive thoughts and feelings, rings around the edge of the patient's cornea, tremors, and stiff muscles. Wilson’s disease shows all of these symptoms. Moreover, retail pharmacy demand for Penicillamine, Trientine, and Zinc drugs has increased by 48%. All of these factors are increasing demand for the Wilson disease drugs market and are expected to grow during the forecast period. Various organizations are raising awareness about Wilson's disease, which will drive market growth.

Wilson's disease association, based in New York, is a volunteer organization dedicated to promoting the well-being of Wilson's disease patients by providing up-to-date information on the disease, its symptoms, and treatment. Moreover, Wilson's disease association funds research and clinical trials for Wilson's disease.

Growing prevalence of chronic pain

Increasing prevalence of chronic pain diseases is expected to drive growth in the Wilson disease drugs market. For example, according to data published by the National Center for Biotechnology Information, the Centers for Disease Control and Prevention (CDC) estimated 51.2 million U.S. adults experienced chronic pain in February 2022 using data from the 2019 National Health Interview Survey (NHIS). A second CDC publication from the National Health Interview Survey (NHIS) discovered that 22.1% of these U.S. adults with chronic pain used prescription opioids.

Furthermore, according to data from the National Health Interview Survey (NHIS), the prevalence of chronic pain was 20.4% globally in February 2022, and the prevalence of high-impact chronic pain was 7.4% (or 36.4% of adults with chronic pain). Globally, women (21.7%), non-Hispanic white adults (23.6%), and those aged 65 and up (30.8%) had the highest rates of chronic pain.
Wilson Disease Drugs Market Restraints
Adverse effects of the drug caused by the high dosage

People are consuming high doses of drugs even prescribed with low doses by doctors, putting a strain on the Wilson disease drugs market. The patient's health is suffering as a result of the high dose. As a result, the death rate is rising, and people are avoiding treatment with the Wilson disease drug. Additionally, the Lack of awareness and diagnosis facilities associated with Wilson's disease treatment are major factors hampering growth in the global Wilson's disease drug market. Wilson's disease, for example, is a rare autosomal recessive disorder, according to data published by the National Center for Biotechnology Information (NCBI) in April 2019, and no single examination can unequivocally confirm or exclude the disease.

Wilson Disease Drugs Market Opportunity

Increasing government initiatives for research and development

Increasing government initiatives, such as funding by government organizations for pain management drug research and development, are expected to drive the Wilson disease drugs market. For example, the National Institute of Neurological Disorders and Stroke (NINDS) launched the Anticonvulsant Drug Development (ADD) Program in May 2022 to actively participate in the early identification and characterization of novel investigational anticonvulsant drugs for the symptomatic treatment of epilepsy. The Anticonvulsant Drug Development (ADD) program serves as the department's focal point for epilepsy-related research.

The primary goal of this program is to identify potential new antiepileptic agents, and the work is supported by a long-term National Institute of Health (NIH) research contract for anticonvulsant drug early evaluation. The project employs preclinical seizure models and neuroscience techniques to aid in the development of new antiepileptic drugs. Every year, approximately 800-1000 new compounds are tested against conventional drugs for anticonvulsant efficacy and potency, neurotoxicity, effect on liver function, and mechanism of action.
Wilson Disease Drugs Market Segment Analysis:
Based on Drug Type, The Wilson disease drugs market is classified as Penicillamine, Trientine, and Zinc. Due to an increase in Wilson disease incidence and the pharmaceutical industry and research organizations being forced to focus on the discovery of a treatment for Wilson disease, the Penicillamine segment was the major revenue contributor to Wilson disease drugs market share in 2022 and is expected to continue this trend during the forecast period. Moreover, key players' ongoing research initiatives and the deployment of innovative technology in this market, as well as significant government and private sector funding in Wilson disease research, are driving the market growth.

The Trientine segment, on the other hand, is expected to grow at the fastest rate during the forecast period, owing to an increase in the approval of Wilson's disease treatment drugs by regulatory authorities. Additionally, increases in healthcare spending and government support and initiatives undertaken by countries to work on R&D activities for Wilson disease drugs development will help the market for Wilson disease drugs grow even more in the forecast period.



Based on the Application, The pharmacy market is divided into three segments: hospital pharmacy, retail pharmacy, and online pharmacy. Due to the increase in Wilson disease patients, the growing number of independent pharmacies and chains, and the availability of medications in supermarkets and mass retailers, the retail pharmacy segment was the major revenue contributor to Wilson disease drugs market share in 2022 and is expected to continue this trend during the Wilson disease drugs market forecast. Additionally, the rapid adoption of automation technologies such as pharmacy robots, dispensing, and packaging systems are boosting the segment forward.
Wilson Disease Drugs Market Regional Insights:
North America has the largest share of the Wilson Disease Drugs market, with the United States contributing the most revenue. Factors such as rising geriatric demand for long-term disease drug management and advancements in the Wilson Disease Drugs field are expected to drive market growth in North America. Furthermore, according to PubMed data from 2022, the prevalence of chronic pain in Americans is rising. Every year, one in every five people in the region suffers from chronic pain. Because it is one of the most common chronic conditions in the United States, there is a growing demand for Wilson Disease Drugs across the country.

Furthermore, according to the American Society of Regional Anesthesia and Pain Medicine (ASRA), chronic opioid therapy and the use of steroids in interventional pain procedures may induce immune suppression, which is critical because it reduces the chances of fighting several viral infections. As a result, all of the aforementioned factors are expected to increase demand for the Wilson disease drugs market and drugs during the forecast period.

Overall, the Wilson disease drugs market in the United States is considered highly competitive, owing to the significant presence of pain specialist physicians, the increasing trend of FDA product approvals, and the robust infrastructure for providing pain management services to patients. For example, upon approval, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. formed a strategic commercialization agreement for rimegepant in markets other than the United States in November 2022.

In the United States, rimegepant is marketed as Nurtec ODT and is indicated for the acute treatment of migraine attacks with or without aura as well as the preventive treatment of episodic migraine in adults. As a result, the market in North America is expected to grow significantly during the forecast period.
Wilson Disease Drugs Market Scope: Inquiry Before Buying



Wilson Disease Drugs Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US$ 637.36 Mn.


Forecast Period 2023 to 2029 CAGR:
4.4%
Market Size in 2029:
US$ 861.6 Mn.


 Segments Covered:
by Drug Type
1. Penicillamine
2. Trientine
3. Zinc


by Distribution Channel
1. Retail Pharmacies
2.Hospital Pharmacies
3. Online Pharmacies


by Route of Administration
1. Oral
2. Parenteral
3. Others


by End-Users
1. Hospitals
2. Homecare
3. Specialty Clinics
4. Others



Wilson Disease Drugs Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Wilson Disease Drugs Market, Key Players are
1. Apotex
2. ANI Pharmaceuticals Inc
3. Teva Pharmaceutical Industries Limited
4. Lupin Ltd
5. Dr.Reddy's Laboratories Ltd
6. Bausch Health Companies Inc.
7. Panacea Biotec Ltd
8. Par pharmaceutical
9. Navinta llc,
10. Breckenridge pharmaceutical, inc.
11. Valeant Pharmaceuticals International, Inc.
12. Noblepharma Co., Ltd.
13. Wilson Therapeutics AB
14. Kadmon Holdings, Inc.
15. Merck & Co., Inc.
16. VHB Life Science Ltd.
17. Tsumura & Co.

Frequently Asked Questions:

1] What segments are covered in the Global Market report?
Ans. The segments covered in the Wilson Disease Drugs Market report are based on Drug Type, Distribution Channel, Route of Administration, End-Users and Region.

2] Which region is expected to hold the highest share in the Global Market?
Ans. The North America region is expected to hold the highest share in the Wilson Disease Drugs Market.

3] What is the market size of the Global  Market by 2029?
Ans. The market size of the Wilson Disease Drugs Market by 2029 is expected to reach US$ 861.6 Mn.

4] What is the forecast period for the Global  Market?
Ans. The forecast period for the Wilson Disease Drugs Market is 2023-2029.

5] What was the market size of the Global  Market in 2022?
Ans. The market size of the Wilson Disease Drugs Market in 2022 was valued at US$ 637.36 Mn.